Drugs / Polyvinyl alcohol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05490381 | Dec 2023 → Jan 2025 | head and neck cancer | University of Washington | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 41 trial | ||||||
| Phase 4 | NCT02752763 | Oct 2015 → Mar 2016 | dry eye syndrome | Niğde State Hospital | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02762266 Comparator | Feb 2016 → Dec 2022 | hepatocellular carcinoma | Stanford University | Terminated | No outcome recorded Stop: Business |
| — | NCT06913816 Background | Mar → Jun 2025 overdue | VISS syndrome | Superior University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyvinyl alcohol | “Routine rehabilitation included the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops.” NCT06913816 ↗3“Refresh single dose(polyvinyl Alcohol + Povidone)” NCT02752763 ↗ “Polyvinyl alcohol (PVA) particles” NCT02762266 ↗ |
| Known as | PVA | “Polyvinyl alcohol (PVA) particles” NCT02762266 ↗ |
| Route | Other | “Given via catheter” NCT05490381 ↗ |